ESR1 and breast cancer: Because a functioning Src axis is required for ER-α coregulator mediated extranuclear actions, a combination of tamoxifen and a Src kinase inhibitor (dasatinib) may be synergistic in ER-α/HER2 expressing tumors, including gastric cancer and tamoxifen resistant breast cancer [100,107].